FRAMINGHAM, Mass.& MEDFORD, Mass.--(BUSINESS WIRE)--SCIEX, a global innovator in life science analytical technologies and Hepregen Corporation, a leader in the development of next-generation, application-directed, cell-based in vitro assay products, today announced a Co-Marketing Agreement to deliver a new metabolite identification (Met ID) solution for drug metabolism scientists. From cell culture to interpretation, this solution provides an extensive view into in vitro data to enable researchers to generate, identify and analyze metabolites in one simple workflow. Customers are guided through the entire workflow, including report generation, with an easy-to-use software solution from start to finish.
This Met ID solution mitigates the chances of downstream drug failure for customers, resulting in higher success rates for drug candidate selection, ensuring that an important metabolite will not be missed.
This Comprehensive Met ID solution includes:
- HepatoPac®: Generates at least 25-30% more metabolites for all drug-development relevant species using in vitro hepatocyte assay
- SWATH® Acquisition: Provides increased capability to capture all data with one injection
- TripleTOF® 6600 LC-MS System: Increases accuracy, speed, and dynamic range for quan-qual workflows
- MetabolitePilotTM Software: Parses data and easily produces reports based on research goals
These combined best-in-class tools and methods offer this complete in vitro metabolite identification, profiling and stability solution, using only micromolar to sub-micromolar amounts of new chemical entities. Drug metabolism scientists can now easily detect potentially reactive, toxic, active, and inactive metabolites at trace levels, with high confidence, and unprecedented speed.
“Until now, particularly in the case of low-turnover compounds, drug metabolism researchers have had significant difficulty predicting in vitro metabolic outcomes with complete confidence,” said Joe Fox, Senior Director of Pharma Business at SCIEX. “Together with Hepregen, we have established this much needed end-to-end solution for our Met ID customers by combining our best-in-class TripleTOF MS instruments, SWATH Acquisition and MetabolitePilot software with HepatoPac kits for the species most relevant for drug development.”
“By combining the proven and comprehensive metabolite-generating capability of Hepregen HepatoPac® kits with the best-in-class SCIEX LC-MS solution, customers can now achieve the highest confidence in their in vitro metabolite results,” said Dr. Vincent Zurawski, Hepregen CEO. “Partnering with SCIEX has enabled Hepregen to offer researchers the most advanced and predictive hepatic metabolite analysis system in the industry.”
Learn more about the SCIEX and Hepregen MetID Solution
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit www.sciex.com.
For Research Use Only. Not for use in Diagnostic Procedures.
AB Sciex is operating as SCIEX.
© 2015 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB SCIEX™ is being used under license.
About Hepregen Corporation
Hepregen Corporation is a leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The company’s micro-liver HepatoPac® and HepatoMuneTM cell-based assays are intended to drive a paradigm shift in drug development. The utilities of Hepregen’s human, rat, monkey, dog, and multi-species/multi-donor HepatoPac® and HepatoMune™ application-directed products have been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures and Innovation Valley Partners with technology licensed from the Massachusetts Institute of Technology. The technology was initially developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.